Augmented Berlin-Frankfurt-Münster (aBFM) Protocol for Acute Lymphoblastic Leukemia
The augmented BFM protocol is a pediatric-inspired, multi-phase chemotherapy regimen consisting of 4-drug induction (vincristine, anthracycline, corticosteroid, asparaginase), followed by consolidation blocks and prolonged maintenance therapy, with mandatory CNS prophylaxis throughout. 1
Core Treatment Structure
The aBFM regimen divides treatment into distinct phases that extend over 2-3 years:
Induction Phase
The backbone consists of a 4-drug combination 1:
- Vincristine (weekly dosing)
- Anthracycline (daunorubicin or doxorubicin)
- Corticosteroid (dexamethasone 6 mg/m² daily for 28 days, preferred over prednisone for superior CNS penetration and reduced CNS relapse risk) 1
- Asparaginase (calaspargase preferred for patients ≤21.5 years if available; pegaspargase as alternative) 1
Critical distinction: Standard-risk pediatric patients may receive 3-drug induction without anthracyclines, but the augmented protocol intensifies therapy for higher-risk patients 1.
Consolidation/Intensification Phases
The augmented protocol provides prolonged, intensified post-induction chemotherapy compared to standard BFM 2. This includes:
- Early intensification block
- CNS-directed therapy phase (mandatory for all patients)
- Delayed intensification (often doubled in augmented protocols)
- Interim maintenance phases
The consolidation typically involves rotating blocks of chemotherapy 1:
- Block A: Ifosfamide, vincristine, high-dose methotrexate, etoposide, cytarabine
- Block B: Vincristine, cyclophosphamide, methotrexate, doxorubicin
- Block C: Vindesine, methotrexate, etoposide, cytarabine
Each block is repeated, creating 6 total cycles administered every 28 days 3.
Maintenance Phase
Continuation therapy extends for the remainder of the 2-3 year treatment period, including:
- Daily oral mercaptopurine
- Weekly methotrexate
- Periodic vincristine and corticosteroid pulses
- Ongoing intrathecal chemotherapy for CNS prophylaxis 1
CNS Prophylaxis
All aBFM regimens mandate CNS-directed therapy throughout treatment 1:
- Intrathecal chemotherapy administered once per treatment block
- High-dose systemic methotrexate (provides CNS penetration)
- Dexamethasone (superior CNS penetration compared to prednisone) 1
Clinical Outcomes and Evidence
The augmented protocol demonstrates superior efficacy compared to standard BFM, particularly for high-risk patients:
- Pediatric data: 4-year event-free survival of 70.8% in slow early responders treated with aBFM, effectively abrogating the adverse prognosis of delayed response 2
- Adult/AYA data: 5-year overall survival of 60-74% in patients aged 12-40 years, with complete remission rates of 93-94% 4, 5
- Risk stratification matters: The protocol's intensification specifically benefits patients with unfavorable presenting features, slow early response, or high-risk cytogenetics 2, 6
Toxicity Profile
Asparaginase-related toxicities dominate the aBFM safety profile 4, 5:
- Hepatotoxicity: 35-41% (typically transient)
- Pancreatitis: 11%
- Thrombosis: 19-22%
- Allergic reactions to E. coli asparaginase: 35% (requiring switch to ERW-rywn) 2
- Vincristine neuropathy: 50% (rarely debilitating) 2
- Osteonecrosis: 9-11% (particularly with high-dose dexamethasone) 4, 5
Important caveat: These toxicities differ substantially from traditional adult regimens like hyper-CVAD, which cause more myelosuppression-related complications 5.
Risk-Directed Treatment Allocation
The augmented protocol is specifically indicated for 7, 6:
- Intermediate-risk patients <50 years old
- All high-risk patients (defined by age, cytogenetics, peripheral leukocytosis, slow early response)
- Patients with specific high-risk genetic features (e.g., iAMP21) 6
MRD status at day 29 and day 84 predicts long-term outcomes and should guide decisions about allogeneic transplantation 1, 4, 5.
Modern Modifications
Current practice increasingly incorporates 8, 9:
- Rituximab for B-cell ALL (administered day 1 of each block)
- Targeted agents for specific genetic subtypes
- Blinatumomab or inotuzumab ozogamicin integration (particularly for MRD-positive patients)
Transplant consideration: Allogeneic HCT is not routinely recommended in first remission for aBFM-treated patients unless MRD remains positive at end of induction (B-ALL) or end of consolidation (T-ALL) 1, 8.